Allergic Rhinitis - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 135
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A70B561ED33EN
Leaflet:

Download PDF Leaflet

Allergic Rhinitis - Pipeline Review, H2 2017
Allergic Rhinitis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 8, 16, 4, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Allergic Rhinitis - Overview
Allergic Rhinitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Allergic Rhinitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Allergic Rhinitis - Companies Involved in Therapeutics Development
Accolade Pharmaceuticals LLC
AFFiRiS AG
ALK-Abello A/S
AlleCures Inc
Allergy Therapeutics Plc
ASIT Biotech SA
Axikin Pharmaceuticals Inc
Chong Kun Dang Pharmaceutical Corp
Chrysalis BioTherapeutics Inc
Fountain Biopharma Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HAL Allergy BV
Hisamitsu Pharmaceutical Co Inc
Intrommune Therapeutics
J Uriach Y Compania SA
Laboratorios LETI SL
Paradigm Biopharmaceuticals Ltd
Sanofi
Stallergenes Greer plc
Sun Pharma Advanced Research Company Ltd
Taiho Pharmaceutical Co Ltd
Therabron Therapeutics Inc
Xencor Inc
Allergic Rhinitis - Drug Profiles
(fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
(mometasone furoate + olopatadine hydrochloride) - Drug Profile
854-A - Drug Profile
Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile
Allergen for Allergic Rhinitis - Drug Profile
Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
arabinogalactan - Drug Profile
B-244 - Drug Profile
bepotastine besilate SR - Drug Profile
BM-41 - Drug Profile
CBP-174 - Drug Profile
CG-201 - Drug Profile
CPC-888 - Drug Profile
emedastine difumarate - Drug Profile
FB-825 - Drug Profile
gp-ASIT - Drug Profile
GSK-2245035 - Drug Profile
hdm-ASIT - Drug Profile
KR-62980 - Drug Profile
Lactococcus lactis G121 - Drug Profile
levocabastine hydrochloride + mometasone furoate - Drug Profile
mometasone furoate - Drug Profile
Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile
nasapaque - Drug Profile
NVP-1703 - Drug Profile
pentosan polysulfate sodium - Drug Profile
Pollinex Quattro Tree - Drug Profile
rag-ASIT - Drug Profile
rupatadine - Drug Profile
short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
Small Molecule for Allergic Rhinitis - Drug Profile
Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
Small Molecules for Respiratory Disorders - Drug Profile
Small Molecules for Seasonal Allergic Rhinitis - Drug Profile
Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile
Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
STG-120 - Drug Profile
SUN-0597 - Drug Profile
SYM-001 - Drug Profile
TAS-205 - Drug Profile
TO-206 - Drug Profile
Vaccine for Asthma and Allergic Rhinitis - Drug Profile
Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
XmAb-7195 - Drug Profile
Zafi-3 - Drug Profile
Allergic Rhinitis - Dormant Projects
Allergic Rhinitis - Discontinued Products
Allergic Rhinitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Allergic Rhinitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2017
Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2017
Allergic Rhinitis - Pipeline by AlleCures Inc, H2 2017
Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2017
Allergic Rhinitis - Pipeline by ASIT Biotech SA, H2 2017
Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals Inc, H2 2017
Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
Allergic Rhinitis - Pipeline by Fountain Biopharma Inc, H2 2017
Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2017
Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2017
Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
Allergic Rhinitis - Pipeline by Intrommune Therapeutics, H2 2017
Allergic Rhinitis - Pipeline by J Uriach Y Compania SA, H2 2017
Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H2 2017
Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Allergic Rhinitis - Pipeline by Sanofi, H2 2017
Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2017
Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Allergic Rhinitis - Pipeline by Therabron Therapeutics Inc, H2 2017
Allergic Rhinitis - Pipeline by Xencor Inc, H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.1), H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.2), H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.3), H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.4), H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.5), H2 2017
Allergic Rhinitis - Dormant Projects, H2 2017 (Contd.6), H2 2017
Allergic Rhinitis - Discontinued Products, H2 2017
Allergic Rhinitis - Discontinued Products, H2 2017 (Contd.1), H2 2017

LIST OF FIGURES

Number of Products under Development for Allergic Rhinitis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Accolade Pharmaceuticals LLC
AFFiRiS AG
ALK-Abello A/S
AlleCures Inc
Allergy Therapeutics Plc
ASIT Biotech SA
Axikin Pharmaceuticals Inc
Chong Kun Dang Pharmaceutical Corp
Chrysalis BioTherapeutics Inc
Fountain Biopharma Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
HAL Allergy BV
Hisamitsu Pharmaceutical Co Inc
Intrommune Therapeutics
J Uriach Y Compania SA
Laboratorios LETI SL
Paradigm Biopharmaceuticals Ltd
Sanofi
Stallergenes Greer plc
Sun Pharma Advanced Research Company Ltd
Taiho Pharmaceutical Co Ltd
Therabron Therapeutics Inc
Xencor Inc
Skip to top


Allergic Asthma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 181 pages
Allergic Asthma - Pipeline Review, H1 2016 US$ 2,000.00 Feb, 2016 · 182 pages

Ask Your Question

Allergic Rhinitis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: